Clinical trials: GEJ Adenocarcinoma
Gastric Cancer
A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer
This is a Phase 3, multicenter, randomized, double-blind, placebo controlled study of Rilotumumab (AMG 102) with Cisplatin and Capecitabine (CX) for untreated advanced mesenchymal epithelial transition factor (MET)-positive…
- Trial name
- RILOMET-2 (NCT02137343)
- Testing
- Rilotumumab, Cisplatin, Capecitabine
- Where
- 25 sites in Japan, South Korea
- Volunteers
- 34 people
- Sponsor
- Amgen
Gastric Cancer, GastroEsophageal Cancer
Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma
The study is a prospective, single arm, phase II trial aimed to evaluate the efficacy and safety of Tumor Treating Fields (TTFields) concomitant with XELOX for the treatment of unresectable, locally advanced or metastatic…
- Trial name
- NCT04281576
- Testing
- NovoTTF-100L(P), Oxaliplatin, Capecitabine
- Where
- Hong Kong
- Volunteers
- 28 people
- Sponsor
- NovoCure Ltd.
Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer
The purpose of this study is to evaluate the efficacy and safety of sintilimab+ IBI310 for EBV-Positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- Trial name
- NCT04202601
- Testing
- Sintilimab, IBI310
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking University
Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC)
NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma
The main purposes of the dose escalation part of this study is to determine the following in participants with gastric or gastro-esophageal junction (GEJ) or esophageal adenocarcinoma (EAC): Safety and tolerability of NT-I7 in…
- Trial name
- NCT04594811
- Testing
- NT-I7, Nivolumab
- Where
- 6 sites in United States, Poland
- Volunteers
- 10 people
- Sponsor
- NeoImmuneTech
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma
This is a phase III, multi-Center, randomized, placebo-controlled trial to investigate the efficacy and safety of CS1001 in combination with Oxaliplatin and Capecitabine (CAPOX) chemotherapy in first-line subjects with…
- Trial name
- NCT03802591
- Testing
- CS1001 monoclonal antibody, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 479 people
- Sponsor
- CStone Pharmaceuticals
PD-L1 Positive Locally Advanced Patients With Resectable Gastric Cancer
A Prospective, Single Center Clinical Study of Toripalimab Combined With FLOT Regimen for Perioperative Treatment of PD-L1 Positive Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GEJ)
In this study, patients with PD-L1 positive locally advanced patients with resectable gastric cancer or gastroesophageal junction adenocarcinoma were invited to participate in the study.To evaluate the efficacy and safety of…
- Trial name
- NCT05466019
- Testing
- Drug: Toripalimab, FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Hospital of Jilin University
Renal Cell Carcinoma, Non Small Cell Lung Cancer
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.
- Conditions
- Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Colo-rectal Cancer (dMMR/MSI-H CRC)
- Trial name
- PSI-Immune (NCT07223424)
- Testing
- nivolumab, pembrolizumab
- Where
- United States
- Volunteers
- 880 people
- Sponsor
- Diwakar Davar
Barrett Esophagus, Barrett Esophagus Adenocarcinoma
A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurrence and the Effect of Risk Profile Disclosure on Patient Quality of Life and Fear of Cancer
The goal of the study is: The collection of various tissue samples (blood, biopsies and "esophageal brushes") and their analysis.
- Conditions
- Barrett Esophagus, Barrett Esophagus Adenocarcinoma, Adenocarcinoma - GEJ, Gastroenterology
- Trial name
- Endeavor-2 (NCT07455422)
- Testing
- Risk profile disclosure
- Where
- 10 sites in Belgium, Denmark and 5 more
- Volunteers
- 266 people
- Sponsor
- University Hospital, Antwerp
Esophagogastric Adenocarcinoma
Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma
This is a multicenter, single arm, prospective, open-label phase II trial investigating the clinical activity of a first-line therapy consisting of induction chemotherapy plus pembrolizumab (12 weeks of mod.
- Trial name
- NCT05268510
- Testing
- Pembrolizumab, Olaparib, mFOLFOX-6
- Where
- Germany
- Volunteers
- 31 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive…
- Trial name
- NCT03615326
- Testing
- Pembrolizumab, Cisplatin, 5-FU
- Where
- 192 sites in United States, Australia and 18 more
- Volunteers
- 738 people
- Sponsor
- Merck Sharp & Dohme LLC
Advance Solid Tumors
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
- Trial name
- NCT07229313
- Testing
- KIVU-107
- Where
- 7 sites in United States, Australia
- Volunteers
- 76 people
- Sponsor
- Kivu Bioscience Inc.
Esophagogastric Adenocarcinoma
Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma
The study is a open-label, single-arm, multicenter, phase Ib/II trial assessing the efficacy of sacituzumab-govitecan for metastatic esophagogastric adenocarcinoma
- Trial name
- NCT06123468
- Testing
- Sacituzumab govitecan
- Where
- 8 sites in Austria, Germany
- Volunteers
- 58 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Stomach Neoplasms
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension
The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in combination with chemotherapy (Cisplatin combined with 5-Fluorouracil [FP regimen] or oxaliplatin combined with capecitabine [CAPOX regimen])…
- Trial name
- NCT04859582
- Testing
- Pembrolizumab, Cisplatin, 5-fluorouracil
- Where
- 28 sites in China
- Sponsor
- Merck Sharp & Dohme LLC
Esophageal Cancer, Adenocarcinoma, Esophageal
Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma
The best treatment for resectable esophageal or gastroesophageal adenocarcinoma is unknown. Although an operation to remove the esophagus is the most common treatment, previous studies have shown that patients live longer when…
- Conditions
- Esophageal Cancer, Adenocarcinoma, Esophageal, Adenocarcinoma, Gastroesophageal Junction
- Trial name
- POWERRANGER (NCT01404156)
- Testing
- (Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel, Carboplatin paclitaxel plus concurrent radiotherapy
- Where
- 3 sites in Canada
- Volunteers
- 29 people
- Sponsor
- Dr. Gordon Buduhan
Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma
Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ
Gastric cancer is one of the most common and deadly cancers globally, characterized by a poor prognosis. Approximately 70% of patients are diagnosed at an advanced stage, and the 5-year survival rate is only around 10%.
- Trial name
- NCT06985602
- Testing
- Arm 1: Adebrelimab Combined with Chemoradiotherapy Followed by Surgery
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Carcinoma, Hepatocellular, Gastric/Gastroesophageal Junction Cancer
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of sitravatinib as monotherapy and in combination with tislelizumab in participants with unresectable locally…
- Trial name
- NCT03941873
- Testing
- Sitravatinib, Tislelizumab
- Where
- 18 sites in China
- Volunteers
- 111 people
- Sponsor
- BeiGene
Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ Adenocarcinoma
This is an open-label, prospective, interventional study designed to enroll 34 patients with locally advanced gastric or gastroesophageal junction adenocarcinoma, aiming to evaluate and observe the efficacy and safety of QL1706…
- Trial name
- NCT07828873
- Testing
- Iparomlimab and Tuvonralimab Injection (QL1706), Docetaxel, Oxaliplatin
- Where
- China
- Volunteers
- 34 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.
- Conditions
- Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
- Trial name
- NCT05002127
- Testing
- Evorpacept (ALX148), Trastuzumab, Ramucirumab
- Where
- 83 sites in United States, Australia and 10 more
- Volunteers
- 127 people
- Sponsor
- ALX Oncology Inc.
Advanced Cancer, Advanced Malignancies
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
- Conditions
- Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer
- Trial name
- ARC-25 (NCT05891171)
- Testing
- AB598, Zimberelimab, Fluorouracil
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 40 people
- Sponsor
- Arcus Biosciences, Inc.
Gastric Cancer, Gastroesophageal-junction Cancer
A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer
The purpose of this study is to find out whether adding cadonilimab to the usual chemotherapy approach is an effective and safe treatment for participants with locally advanced/resectable gastric cancer or gastroesophageal…
- Trial name
- NCT07631000
- Testing
- Cadonilimab
- Where
- 7 sites in United States
- Volunteers
- 37 people
- Sponsor
- Memorial Sloan Kettering Cancer Center